Home » Sanofi Pasteur Chooses Intercim for Mastering Manufacturing Processes
Sanofi Pasteur Chooses Intercim for Mastering Manufacturing Processes
PharmaManufacturing.com
04/14/2010
Intercim, announces that Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, is accelerating the use of Pertinence Suite, Manufacturing Operations Management (MOM) software solution, within the European and North American sites of the worldwide leader of vaccines.
Vaccines come from complex biological processes. The understanding of such manufacturing process is one of the key elements to master products quality and production units performances. Since 2003, Sanofi Pasteur has used the Pertinence Suite solution to better understand, improve reliability and optimize industrial processes.
Rene Labatut, Vice President Manufacturing of Sanofi Pasteur explains: "Manufacturing, and guaranteeing the highest level of quality and safety for the patient, and the optimum performances for the company, are key objectives of process understanding. It is also a corporate challenge in the current competitive environment. The use of Pertinence Suite for understanding mechanisms which drive our complex processes is an asset that provides answers to this double requirement in an efficient manner".
The new deployment of Pertinence Suite demonstrates the willingness to implement in a very operational manner the approach promoted by the regulatory bodies through the ICH Quality by Design (QbD). This approach aims at mastering manufacturing processes and efficiently, while sharing with the authorities the understanding of the mechanisms which drive products critical quality attributes.
Yann d'Aramon, Director Europe of Intercim adds: "We are very pleased of Sanofi Pasteur decision to spread the use of our solutions through their plants around the world. With our solutions, Sanofi Pasteur can identify and set up in real-time, parameters influencing the product quality, and moving forward, better control process variability. This is a recurrent challenge for the pharmaceutical industry which needs to consistently deliver vaccines on time, with a perfect traceability."
About Intercim
Intercim has a 27-year history of helping advanced and highly regulated manufacturers reach their business goals through best in class software solutions. Early 2009, Dassault Systemes a world leader in 3D and Product Lifecycle Management took a minority position in Intercim. Both companies consider critical that information exchange and collaboration between engineering, manufacturing and the supply network be handled in real-time. For the first time, the combination of Intercim's software capabilities with the virtual experience provided by Dassault Systemes' solutions allows this type of mission-critical collaboration and knowledge sharing.
Intercim works mainly for advanced and highly regulated industries and with industry-leading customers such as Boeing, Sanofi Pasteur, Ball Aerospace, BMW, and Honeywell.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page